Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-301 bemarituzumab monotherapy basket study in FGFR2b-overexpressing solid tumors
jRCT2031220301Phase 2Suspended
- Sponsor
- Amgen
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of bemarituzumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC) and 7 more (2 arms), sponsored by Amgen. Primary endpoints: Number of participants who experience a dose-limiting toxicity, Number of participants who experience a treatment-emergent adverse event and 2 more. Started Sep 2022; status: suspended.
02
Drugs
bemarituzumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)intrahepatic cholangiocarcinoma (ICC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2031220301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220301.